Context Therapeutics (CNTX)
Market Price (3/30/2026): $2.55 | Market Cap: $242.7 MilSector: Health Care | Industry: Biotechnology
Context Therapeutics (CNTX)
Market Price (3/30/2026): $2.55Market Cap: $242.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -40 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 185%, 12M Rtn12 month market price return is 295% | |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% | |
| Key risksCNTX key risks include [1] its history of unprofitability and need for future funding, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -27% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -40 Mil |
| Stock price has recently run up significantly6M Rtn6 month market price return is 185%, 12M Rtn12 month market price return is 295% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19% |
| Key risksCNTX key risks include [1] its history of unprofitability and need for future funding, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Context Therapeutics (CNTX) stock has gained about 130% since 11/30/2025 because of the following key factors:
1. Encouraging early clinical data from the CTIM-76 Phase 1a trial demonstrated preliminary anti-tumor activity, including an 85% tumor reduction in a platinum-resistant ovarian cancer patient, alongside a favorable safety profile with no Cytokine Release Syndrome greater than Grade 1 or dose-limiting toxicities reported as of November 2025.
2. The company announced a robust pipeline with clear developmental milestones, including anticipated Phase 1a interim data for its CTIM-76 trial in June 2026, Phase 1a interim data for its CT-95 trial in September 2026, and plans to dose the first patient in its CT-202 Phase 1 trial in the third quarter of 2026.
Show more
1. Encouraging early clinical data from the CTIM-76 Phase 1a trial demonstrated preliminary anti-tumor activity, including an 85% tumor reduction in a platinum-resistant ovarian cancer patient, alongside a favorable safety profile with no Cytokine Release Syndrome greater than Grade 1 or dose-limiting toxicities reported as of November 2025.
2. The company announced a robust pipeline with clear developmental milestones, including anticipated Phase 1a interim data for its CTIM-76 trial in June 2026, Phase 1a interim data for its CT-95 trial in September 2026, and plans to dose the first patient in its CT-202 Phase 1 trial in the third quarter of 2026.
Show more
Stock Movement Drivers
Fundamental Drivers
The 131.2% change in CNTX stock from 11/30/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.12 | 2.59 | 131.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 95 | 95 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CNTX | 131.2% | |
| Market (SPY) | -5.3% | -7.0% |
| Sector (XLV) | -8.7% | -5.9% |
Fundamental Drivers
The 208.3% change in CNTX stock from 8/31/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.84 | 2.59 | 208.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 95 | 95 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CNTX | 208.3% | |
| Market (SPY) | 0.6% | 3.3% |
| Sector (XLV) | 5.2% | -3.2% |
Fundamental Drivers
The 191.8% change in CNTX stock from 2/28/2025 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.89 | 2.59 | 191.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 80 | 95 | -15.4% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CNTX | 191.8% | |
| Market (SPY) | 9.8% | 16.0% |
| Sector (XLV) | -2.1% | 12.2% |
Fundamental Drivers
The 236.4% change in CNTX stock from 2/28/2023 to 3/29/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.77 | 2.59 | 236.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 16 | 95 | -83.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CNTX | 236.4% | |
| Market (SPY) | 69.4% | 15.2% |
| Sector (XLV) | 18.4% | 10.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CNTX Return | -48% | -76% | 73% | -7% | 40% | 73% | -50% |
| Peers Return | -33% | -38% | -29% | -55% | -48% | 8% | -93% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| CNTX Win Rate | 67% | 42% | 50% | 58% | 67% | 67% | |
| Peers Win Rate | 31% | 44% | 44% | 36% | 50% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CNTX Max Drawdown | -48% | -77% | -26% | -19% | -48% | -2% | |
| Peers Max Drawdown | -40% | -52% | -49% | -60% | -61% | -24% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, AKTS, ALPS, DCOY, DFTX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | CNTX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -93.5% | -25.4% |
| % Gain to Breakeven | 1445.6% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to VRTX, AKTS, ALPS, DCOY, DFTX
In The Past
Context Therapeutics's stock fell -93.5% during the 2022 Inflation Shock from a high on 10/25/2021. A -93.5% loss requires a 1445.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Context Therapeutics (CNTX)
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
AI Analysis | Feedback
1. AstraZeneca for early-stage women's cancer drugs.
2. Genentech for novel gynecologic cancer therapies.
AI Analysis | Feedback
```html- Onapristone extended release (ONA-XR): A progesterone receptor antagonist aimed at overcoming resistance to cancer therapeutics in female hormone-dependent cancers.
- CLDN6xCD3 bsAb: A bispecific monoclonal antibody designed to redirect T-cell-mediated lysis against malignant cells expressing CLDN6.
AI Analysis | Feedback
Context Therapeutics (CNTX) is a clinical-stage biopharmaceutical company focused on developing product candidates for the treatment of cancer. As such, the company is currently engaged in research and development and has not yet brought any products to market for commercial sale. Therefore, Context Therapeutics does not currently have major customers purchasing its products.
AI Analysis | Feedback
Integral Molecular, Inc.
AI Analysis | Feedback
Martin Lehr, Chief Executive Officer
Mr. Lehr is the Co-founder and CEO of Context Therapeutics. He was previously part of the founding team at Osage University Partners, a venture capital fund that invested in technologies from academic universities, focusing on early-stage oncology and rare disease opportunities. Mr. Lehr conducted research at the Sloan Kettering Institute and the Children's Hospital of Philadelphia. He also serves on the Boards of Praesidia Biologics and CureDuchenne Ventures and is a Director of BioBreak.
Jennifer Minai-Azary, Chief Financial Officer
Ms. Minai-Azary was appointed Chief Financial Officer of Context Therapeutics in November 2021.
Karen Chagin, MD, Chief Medical Officer
Dr. Chagin is the Chief Medical Officer of Context Therapeutics. Before joining Context, she served as Senior Vice President of Early-Stage Development at Adaptimmune, where she played a critical role in the development and approval of Tecelra (afamitresgene autoleucel). She also held positions of increasing responsibility, culminating as Chief Medical Officer, at Tmunity from 2019 to 2023.
Alex Levit, Esq, Chief Legal Officer
Mr. Levit was appointed Chief Legal Officer of Context Therapeutics in April 2021.
Christopher Beck, MBA, SVP of Operations
Mr. Beck joined Context Therapeutics in January 2022 as SVP of Operations. He is a pharmaceutical leader with a 30-year career spanning private, public, startup, and high-growth Pharmaceutical and Biotech companies. Previously, Mr. Beck served as Vice President Program Management at Galera Therapeutics.
AI Analysis | Feedback
Context Therapeutics Inc. (CNTX) faces several key risks inherent to its nature as a clinical-stage biopharmaceutical company.
- Clinical Development and Regulatory Approval Risk: As a company primarily focused on developing novel treatments for cancer, Context Therapeutics' success hinges on the successful outcome of its ongoing clinical trials for product candidates such as CTIM-76, CT-95, and CT-202. There is a significant risk that these product candidates may fail to demonstrate efficacy or sufficient safety profiles during preclinical and clinical testing, or may not receive the necessary regulatory approvals (e.g., from the FDA) required for commercialization. Such failures would materially and adversely affect the company's business, financial condition, and prospects.
- Funding and Capital Requirements Risk: Context Therapeutics is a clinical-stage company with a limited operating history and no products currently generating revenue from sales. Consequently, the company is highly dependent on raising substantial additional capital to fund its research and development activities, conduct clinical trials, and support its operations through to potential commercialization. While the company has reported a cash runway extending into 2027, it will require significant future financing. An inability to secure this additional funding on favorable terms or at all could force the company to delay, reduce, or terminate its product development programs or other business operations.
- Limited Operating History and Commercialization Risk: Given its status as a clinical-stage biopharmaceutical company, Context Therapeutics has a limited operating history and has not yet successfully commercialized any products or generated product sales revenue. This makes it challenging to evaluate the company's business and future prospects. Even if product candidates successfully complete clinical trials and obtain regulatory approval, there is no guarantee that the company will be able to successfully commercialize them, achieve market acceptance, build necessary sales and marketing infrastructure, or generate significant sales, all of which are crucial for sustained profitability.
AI Analysis | Feedback
BioNTech's CLDN6 CAR-T program (BNT211) represents a clear emerging threat. While Context Therapeutics is developing a CLDN6xCD3 bispecific antibody to target CLDN6-expressing malignant cells in gynecologic cancers, BioNTech has a CLDN6-targeted CAR-T cell therapy (BNT211) that has shown promising early clinical data in solid tumors, including ovarian cancer and testicular cancer, which fall under the relevant cancer types. CAR-T cell therapy is a distinct and potentially more potent therapeutic modality compared to bispecific antibodies for targeting specific antigens on cancer cells. If BioNTech's CLDN6 CAR-T continues to demonstrate superior efficacy or durability, it could significantly disrupt the market potential for Context Therapeutics' CLDN6 bispecific antibody program by offering a more impactful treatment option for the same patient population and target, akin to a newer, more advanced technology challenging an existing approach.
AI Analysis | Feedback
Context Therapeutics' main products target significant addressable markets in oncology. For their lead product candidate, onapristone extended release (ONA-XR), a progesterone receptor antagonist for female hormone-dependent cancers: * Analysts estimate a combined peak sales potential of approximately $1 billion for ONA-XR in the U.S. alone. * The broader global progesterone market, which includes therapies for hormone-related conditions and cancers, was valued at approximately USD 1.5 billion in 2024 and is projected to reach USD 4.27 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 12.3% from 2025 to 2033. * Within this market, endometrial cancer protocols are the fastest-growing application, with an estimated CAGR of 11.55% through 2031. For their second product candidate, CLDN6xCD3 bsAb, a bispecific monoclonal antibody targeting Claudin 6 (CLDN6) for gynecologic cancer therapy: * The global bispecific antibodies market, which includes such advanced cancer treatments, was valued at approximately USD 8.65 billion in 2023. This market is projected to reach USD 109.4 billion by 2032, with a CAGR of 34.8% from 2023 to 2032. * More specifically, the global bispecific antibodies in precision oncology market reached US$12.46 billion in 2024 and is expected to reach US$332.77 billion by 2033, growing at a CAGR of 44.05% from 2026 to 2033. North America holds a dominant share, capturing 38.5% of this market in 2025. * CLDN6 is considered a compelling target for solid tumors, particularly in ovarian and testicular cancers. * The global gynecological cancer drugs market, which CLDN6xCD3 bsAb targets, was valued at US$17.8 billion in 2024 and is projected to reach US$24 billion by 2030, with a CAGR of 5.1% from 2024 to 2030. The U.S. market for gynecological cancer drugs was valued at $4.9 billion in 2024. North America dominated the gynecological cancer drugs market revenue in 2025. The ovarian cancer segment within this market is expected to exhibit the fastest growth.AI Analysis | Feedback
Context Therapeutics Inc. (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, is focused on developing novel treatments for solid tumors, particularly female cancers. As the company does not currently have commercialized products, analysts forecast zero revenue for 2026 and 2027. However, projections indicate the potential for significant revenue growth beginning in 2028. The primary drivers of future revenue growth for Context Therapeutics over the next 2-3 years are expected to stem from the advancement and potential commercialization of its pipeline of T-cell engaging bispecific antibodies, alongside strategic partnerships.
The key expected drivers of future revenue growth include:
- Successful Clinical Development and Potential Commercialization of CTIM-76: CTIM-76 is a selective Claudin 6 (CLDN6) x CD3 bispecific antibody being developed for CLDN6-positive tumors. The company initiated a Phase 1 clinical trial for CTIM-76 in January 2025, targeting ovarian, endometrial, and testicular cancers. Initial dose escalation data from this trial are anticipated in the first half of 2026. Positive clinical outcomes and subsequent regulatory approvals would be a significant driver for future revenue.
- Advancement and Potential Commercialization of CT-95: CT-95 is an avidity-enhanced mesothelin (MSLN) x CD3 bispecific antibody. Context Therapeutics began a Phase 1 clinical trial for CT-95 in April 2025, focusing on patients with mesothelin-expressing cancers, including ovarian, pancreatic, and mesothelioma. Initial clinical data for CT-95 are expected by mid-2026. Favorable trial results leading to further development and eventual market entry would contribute to revenue growth.
- Progress in Clinical Development of CT-202: CT-202 is a Nectin-4 x CD3 bispecific antibody. The company expects to complete the necessary regulatory filings to initiate a first-in-human trial for CT-202 in the second quarter of 2026. Successful progression of this candidate through clinical trials could also open avenues for future revenue generation.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage company, Context Therapeutics could generate revenue through collaborations, licensing deals, and milestone payments. Analysts have highlighted the potential for CTIM-76 to attract partnerships due to its unique mechanism. Such agreements could provide upfront payments, research funding, and future royalties on product sales if their pipeline candidates are successfully developed and commercialized by partners.
AI Analysis | Feedback
Share Issuance
- Context Therapeutics expanded its at-the-market (ATM) equity offering program to an aggregate amount of $75 million on October 24, 2025.
- Prior to this amendment, the company had sold approximately $15 million worth of shares under the previous ATM arrangement.
- The net proceeds from these offerings are designated for research and development of product candidates, working capital, general corporate purposes, and potentially for acquiring additional assets.
Outbound Investments
- Context Therapeutics acquired CT-95 in July 2024.
- The company in-licensed CT-202 in September 2024.
Capital Expenditures
- Context Therapeutics reported capital expenditures of approximately -$17.0 thousand in 2025.
- Capital expenditures were approximately -$33,948 over the 12 months leading up to Q3 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Context Therapeutics Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CNTX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.74 |
| Mkt Cap | 0.2 |
| Rev LTM | 0 |
| Op Inc LTM | -22 |
| FCF LTM | -16 |
| FCF 3Y Avg | -15 |
| CFO LTM | -15 |
| CFO 3Y Avg | -15 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.9% |
| Rev Chg 3Y Avg | 10.4% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 37.9% |
| Op Mgn 3Y Avg | 24.7% |
| QoQ Delta Op Mgn LTM | 38.7% |
| CFO/Rev LTM | 30.3% |
| CFO/Rev 3Y Avg | 20.5% |
| FCF/Rev LTM | 26.6% |
| FCF/Rev 3Y Avg | 17.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 9.2 |
| P/EBIT | -0.0 |
| P/E | -0.1 |
| P/CFO | -0.1 |
| Total Yield | -14.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -51.3% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.2% |
| 3M Rtn | 1.0% |
| 6M Rtn | 12.3% |
| 12M Rtn | 12.1% |
| 3Y Rtn | 28.8% |
| 1M Excs Rtn | 3.4% |
| 3M Excs Rtn | 15.0% |
| 6M Excs Rtn | 17.0% |
| 12M Excs Rtn | 0.6% |
| 3Y Excs Rtn | -29.7% |
Price Behavior
Price Behavior
| Market Price | $2.59 | |
| Market Cap ($ Bil) | 0.2 | |
| First Trading Date | 10/20/2021 | |
| Distance from 52W High | -22.9% | |
| 50 Days | 200 Days | |
| DMA Price | $2.46 | $1.36 |
| DMA Trend | up | up |
| Distance from DMA | 5.1% | 90.4% |
| 3M | 1YR | |
| Volatility | 97.6% | 91.5% |
| Downside Capture | -2.53 | -0.13 |
| Upside Capture | -29.68 | 131.34 |
| Correlation (SPY) | -9.5% | 12.3% |
CNTX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.27 | -0.22 | -0.15 | 0.61 | 0.92 | 1.00 |
| Up Beta | 2.61 | 2.37 | 3.20 | 1.17 | 0.38 | 0.87 |
| Down Beta | 2.64 | -0.53 | -0.54 | 0.99 | 0.92 | 0.96 |
| Up Capture | -236% | 200% | 144% | 205% | 331% | 172% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 24 | 34 | 61 | 118 | 334 |
| Down Capture | -135% | -476% | -440% | -147% | 103% | 100% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 15 | 24 | 58 | 125 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNTX | |
|---|---|---|---|---|
| CNTX | 221.3% | 92.4% | 1.67 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | 11.3% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 12.4% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | -1.5% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 8.2% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -1.4% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 9.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNTX | |
|---|---|---|---|---|
| CNTX | -13.1% | 99.0% | 0.28 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | 11.8% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 16.0% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | -1.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 2.9% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 11.0% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 8.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CNTX | |
|---|---|---|---|---|
| CNTX | -6.8% | 99.0% | 0.28 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | 11.8% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 16.0% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | -1.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 2.9% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 11.0% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 8.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/23/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/22/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lehr, Martin A | Chief Executive Officer | Martin Lehr 2000 Trust | Buy | 6102025 | 0.70 | 100,000 | 70,080 | 644,869 | Form |
| 2 | Levit, Alex C | Chief Legal Officer, Corp. Sec | Direct | Buy | 6102025 | 0.58 | 20,000 | 11,520 | 16,704 | Form |
| 3 | Minai-Azary, Jennifer Lynn | Chief Financial Officer | Direct | Buy | 6102025 | 0.64 | 40,010 | 25,486 | 50,966 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.